The Business of Fashion
Agenda-setting intelligence, analysis and advice for the global fashion community.
Agenda-setting intelligence, analysis and advice for the global fashion community.
Beyond extending into cosmetics, Celine is adding to its fragrance assortment with Zouzou, $280.
With notes of caramel, amber and musk, the scent is inspired by young, fashionable women of the 1960s, with designer Hedi Slimane taking inspiration from the fashion and beauty trends of that era. Its name is derived for the affectionate term used for young girls with short hair, or also to convey fondness.
The fashion house originally launched nine scents in 2019, with two more launching in 2021 and 2022. In March, LVMH-owned Celine also announced a broader push into beauty with a debut lipstick, Rouge Triomphe, being available in autumn 2024. A fuller selection is slated to launch in January 2025.
Beauty has been a consistent bright spot for LVMH; in its first-quarter earnings announced last week, its perfume and cosmetics division grew 7 percent.
ADVERTISEMENT
Sign up to The Business of Beauty newsletter, your complimentary, must-read source for the day’s most important beauty and wellness news and analysis.
Learn more:
Sephora, Perfumes and Cosmetics Drive LVMH Sales Growth
Amid a luxury slowdown, strong performance by LVMH’s perfumes and cosmetics and selective retailing divisions show a healthy appetite for beauty.
Disclosure: LVMH is part of a group of investors who, together, hold a minority interest in The Business of Fashion. All investors have signed shareholders’ documentation guaranteeing BoF’s complete editorial independence.
This month, BoF Careers provides essential sector insights to help beauty professionals decode the industry’s creative landscape.
The skincare-to-smoothie pipeline arrives.
Puig and Space NK are cashing in on their ability to tap the growth of hot new products, while L’Occitane, Olaplex and The Estée Lauder Companies are discovering how quickly the shine can come off even the biggest brands.
Demand for the drugs has proven insatiable. Shortages have left patients already on the medications searching for their next dose and stymied new starters.